Tumeric is a supplement with evidence:
Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells.
A Review on Antibacterial, Antiviral, and Antifungal Activity of Curcumin
The use of alternative medicine in the treatment of hepatitis C (not about tumeric)
I rather like the inhibition of cellular entry mechanism.
Given it is in food like curry, and the medications are with or without food I can't see a good reason not to take it adding on the disclaimer that nobody has any idea if it will help DAA SVR (yet).
I can see a great April Fools late breaker abstract submission for EASL entitled:
TITLE: The correlation between consumption of curry and SVR rates in populations on the Indian sub-continent taking generic DAAs
ABSTRACT: It has long been known that the polyphenolic compound curcumin, present in Curcuma longa L. (Zingiberaceae family) has a range of antibacterial, antifungal and antiviral activities. In their seminal paper "Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells." Anggakusuma et al elucidated that the mechanism of action revolves around curcumin's ability to inhibit HCV entry independently of the genotype and into hepatocytes by affecting membrane fluidity thereby impairing virus binding and fusion.
In a rare display of bipartisan co-operation Gilead Science and Bristol Myers Squibb provided 40,000 free patient doses of medication to ensure that the trial results had a decent degree of statistical validity. Participants were allocated into 4 test groups: the tri-curry group assigned to eat curry at every meal, the bi-curry group assigned to eat curry at only lunch and dinner, the mono-curry group assigned to eat curry only at lunch. Attempts to recruit participants for a no-curry test group failed, so this medication was donated to the VA.
RESULTS: SVR rates in the tri-curry group were 99 % +/-1%, in the bi-curry group 98% +/- 1% and in the mono-curry group 97% +/- 1%
CONCLUSION: The SVR rates were higher than expected from previous trials, particularly in the hard to treat GT3 population. We conclude that three curries a day keeps HCV at bay and recommend extending the trial to all 185,000,000 patients with HCV.